Articles avec mandats d'accès public - Erwan BezardEn savoir plus
TotalANRNIHEuropean CommissionGovernment of SpainINSERMSwedish Research CouncilMRCFNSFondazione CariploMichael J Fox FoundationIRSCGovernment of ItalyNSFCParkinson's UKDFGWellcomeFRQSVAAlzheimers's UKNIHRASAPParkinson's Foundation, USAHFSPDoDUSEDCRSNGBanking Foundation "la Caixa"TelethonKnut and Alice Wallenberg FoundationBBSRCZonMwRoyal Society UK
Non disponibles : 15
Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia
D Rylander, M Parent, SS O'Sullivan, S Dovero, AJ Lees, E Bezard, ...
Annals of neurology 68 (5), 619-628, 2010
Exigences : Swedish Research Council
A tale on animal models of Parkinson's disease
E Bezard, S Przedborski
Movement Disorders 26 (6), 993-1002, 2011
Exigences : US National Institutes of Health
Comprehensive mapping of neurotransmitter networks by MALDI–MS imaging
M Shariatgorji, A Nilsson, E Fridjonsdottir, T Vallianatou, P Källback, ...
Nature methods 16 (10), 1021-1028, 2019
Exigences : Swedish Research Council
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys
D Rylander, H Iderberg, Q Li, A Dekundy, J Zhang, H Li, R Baishen, ...
Neurobiology of disease 39 (3), 352-361, 2010
Exigences : Swedish Research Council
A phase 2A trial of the novel mGluR5‐negative allosteric modulator dipraglurant for levodopa‐induced dyskinesia in Parkinson's disease
F Tison, C Keywood, M Wakefield, F Durif, JC Corvol, K Eggert, M Lew, ...
Movement Disorders 31 (9), 1373-1380, 2016
Exigences : US National Institutes of Health, Institut national de la santé et de la …
Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia
MF Bastide, S Dovero, G Charron, G Porras, CE Gross, PO Fernagut, ...
Neurobiology of disease 62, 179-192, 2014
Exigences : Fondazione Cariplo
A critique of available scales and presentation of the Non‐Human Primate Dyskinesia Rating Scale
SH Fox, TH Johnston, Q Li, J Brotchie, E Bezard
Movement disorders 27 (11), 1373-1378, 2012
Exigences : US National Institutes of Health, Fondazione Cariplo
NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology
M Mellone, E Zianni, J Stanic, F Campanelli, G Marino, V Ghiglieri, ...
Neurobiology of disease 121, 338-349, 2019
Exigences : UK Medical Research Council, Fondazione Cariplo, European Commission, Agence …
The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced …
E Rojo-Bustamante, MA Abellanas, P Clavero, ML Thiolat, Q Li, ...
Neurobiology of Disease 118, 64-75, 2018
Exigences : Government of Spain
Premotor parkinsonism models
E Bezard, PO Fernagut
Parkinsonism & Related Disorders 20, S17-S19, 2014
Exigences : Fondazione Cariplo
Engrailed‐1 induces long‐lasting behavior benefit in an experimental Parkinson primate model
N Thomasson, E Pioli, C Friedel, A Monseur, J Lavaur, KL Moya, ...
Movement Disorders 34 (7), 1082-1084, 2019
Exigences : US Department of Veterans Affairs, Institut national de la santé et de la …
High frequency stimulation of the entopeduncular nucleus sets the cortico-basal ganglia network to a new functional state in the dystonic hamster
R Reese, G Charron, A Nadjar, I Aubert, ML Thiolat, M Hamann, A Richter, ...
Neurobiology of disease 35 (3), 399-405, 2009
Exigences : German Research Foundation
Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson’s Disease
S Hagenow, A Affini, EY Pioli, S Hinz, Y Zhao, G Porras, V Namasivayam, ...
Journal of Medicinal Chemistry 64 (12), 8246-8262, 2021
Exigences : German Research Foundation, Institut national de la santé et de la recherche …
Claire Mazzocco, Coralie Genevois 3, Qin Li 4, Evelyne Doudnikoff1, 2, Nathalie Dutheil
T Leste‑Lasserre, ML Arotcarena, E Bezard
Scientific Reports 14, 9710, 2024
Exigences : European Commission, Agence Nationale de la Recherche
A Computational Framework for the Design of Spinal Neuroprostheses
M Capogrosso, E Bezard, J Bloch, G Courtine, S Micera
Converging Clinical and Engineering Research on Neurorehabilitation II …, 2016
Exigences : Fonds national suisse, European Commission
Disponibles quelque part : 146
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms
MC Rodriguez-Oroz, M Jahanshahi, P Krack, I Litvan, R Macias, E Bezard, ...
The Lancet Neurology 8 (12), 1128-1139, 2009
Exigences : US National Institutes of Health
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
JA Obeso, M Stamelou, CG Goetz, W Poewe, AE Lang, D Weintraub, ...
Movement disorders 32 (9), 1264-1310, 2017
Exigences : US National Institutes of Health
A brain–spine interface alleviating gait deficits after spinal cord injury in primates
M Capogrosso, T Milekovic, D Borton, F Wagner, EM Moraud, ...
Nature 539 (7628), 284-288, 2016
Exigences : Fonds national suisse, European Commission
Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys
A Recasens, B Dehay, J Bové, I Carballo‐Carbajal, S Dovero, ...
Annals of neurology 75 (3), 351-362, 2014
Exigences : Government of Spain
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
B Dehay, M Bourdenx, P Gorry, S Przedborski, M Vila, S Hunot, ...
The Lancet Neurology 14 (8), 855-866, 2015
Exigences : US National Institutes of Health, Government of Spain
Les informations concernant la publication et le financement sont déterminées automatiquement par un programme informatique